Table 2.
Characteristics of 15 patients with grade 3 or 4 immune-related adverse events
| Case No. | irAE | CTCAE Grade | Sex | Age, years | Cancer | Treatment | Systemic Steroid Use | Best Response |
|---|---|---|---|---|---|---|---|---|
| 1 | Dermatitis | 3 | Male | 53 | Colorectal | Cytokine | No | PD |
|
| ||||||||
| 2 | Enterocolitis | 3 | Female | 49 | Colorectal | Checkpoint | Yes | SD |
|
| ||||||||
| 3 | LFT elevation | 3 | Male | 60 | GE junction | Combination | Yes | SD |
|
| ||||||||
| 4 | Dermatitis | 3 | Female | 48 | Cervical | Checkpoint | Yes | PD |
|
| ||||||||
| 5 | Enterocolitis | 4 | Male | 73 | Thyroid | Checkpoint | Yes | NE |
|
| ||||||||
| 6 | Autoimmune hepatitis | 3 | Male | 56 | NSCLC | Combination | Yes | PR |
|
| ||||||||
| 7 | Pleuritis (serositis) | 3 | Male | 66 | NSCLC | Cytokine | Yes | SD |
|
| ||||||||
| 8 | Myositis | 4 | Male | 66 | RCC | Checkpoint | Yes | NE |
| Autoimmune hepatitis | 3 | Yes | ||||||
| Myasthenia gravis | 3 | * IV Ig | ||||||
|
| ||||||||
| 9 | Myositis | 4 | Male | 59 | RCC | Checkpoint | Yes | PR |
|
| ||||||||
| 10 | Enterocolitis | 3 | Male | 70 | RCC | Combination | Yes | NE |
|
| ||||||||
| 11 | Pneumonitis | 3 | Female | 71 | Leiomyosarcoma | Vaccine | No | SD |
|
| ||||||||
| 12 | Dermatitis | 3 | Male | 58 | Adenoid cystic carcinoma | Cytokine | No | SD |
|
| ||||||||
| 13 | Dermatitis | 3 | Female | 75 | Hurthle cell carcinoma | Combination | Yes | PD |
|
| ||||||||
| 14 | Pancreatitis | 4 | Male | 59 | Neuroendocrine tumor | Combination | No | PD |
|
| ||||||||
| 15 | Myasthenia gravis | 3 | Male | 71 | Prostate | Checkpoint | Yes | CR |
Abbreviations: CTCAE, Common Terminology Criteria for Adverse Events; GE, gastroesophageal; IV Ig, intravenous immunoglobulin; LFT, liver function test; NE, Not evaluable; NSCLC, non-small cell lung carcinoma; RCC, renal cell carcinoma.
*
In addition to systemic corticosteroid, patient received intravenous immunoglobulin for myasthenia gravis.